OSA is a common sleep disorder characterized by oxygen desaturation due to repeated airway collapse during sleep.

Researchers conduct the first meta-analysis comparing hypnotics in OSA patients, finding most are safe but flagging temazepam ...

A few years ago, drug giant Bristol-Myers Squibb Co. announced it was retooling its strategy, meaning a drug it was developing for insomnia was probably headed for the sidelines. Vanda Pharmaceuticals ...

This Nature Outlook is editorially independent, produced with financial support from Avadel. Miranda cannot remember a time in her life when she did not have insomnia. The 23 year old, who asked for ...

Clinical decision-making is a complex process, driven by multiple factors, including social and psychological dynamics, peer pressure and even exposure to drug advertising. Now research from Harvard ...

TOKYO, May 28, 2025 - (JCN Newswire) - - Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in ...

WASHINGTON — The first generic versions of the insomnia drug Ambien won federal approval Monday. The Food and Drug Administration said it approved versions of the immediate-release tablets made by 13 ...

The U.S. Food and Drug Administration approved Belsomra (suvorexant) tablets for use as needed to treat insomnia. Belsomra is an orexin receptor antagonist and is the first approved drug of this type.

The "Insomnia: Opportunity Assessment and Forecast Update" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM and provides an Excel-based forecast model for the ...

Investigational seltorexant improved symptoms of major depressive disorder (MDD) and insomnia in people with an inadequate response to antidepressants, a phase III trial indicated. By week 6, the ...